No Data
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
C HEALTH GP (08225): Wang Dajun resigned as a non-executive Director.
C HEALTH GP (08225) announced that due to the adjustment of the group's organizational structure and Mr. Wang Dajun's personal...
C HEALTH GP: INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2024
C Health GP (08225.HK): Appointed Guo Ruimeng as executive director and chief artificial intelligence officer.
On September 11th, Guolonghui announced that Dr. Song has resigned from his position as an executive director and supervisory director of c health gp due to the retirement of Song Xuemei, and his resignation will be effective from September 11th, 2024. In addition, Guo Ruimeng has been appointed as an executive director and the Chief Artificial Intelligence Officer (CAIO) of the company, and the appointment will be effective from September 11th, 2024.
Express News | China Health Group Inc - Song Xuemei Tendered Resignation as an Executive Director
C HEALTH GP: Supplementary Announcement on Financial Assistance
